Source comparison
Comparison Table: Sermorelin Timeline vs Alternative GH Protocols
Sermorelin 300–500 mcg nightly 30–45 min post-injection 2–4 weeks 8–12 weeks Excellent. Pulsatile pattern preserves receptor sensitivity Slowest visible timeline but best long-term sustainability; mimics natural GH secretion architecture Exogenous recombinant
This comparison does not assign a generated winner or score.
- Sermorelin 300–500 mcg nightly
- 30–45 min post-injection
- 2–4 weeks
- 8–12 weeks
- Excellent. Pulsatile pattern preserves receptor sensitivity
- Slowest visible timeline but best long-term sustainability; mimics natural GH secretion architecture
- Exogenous recombinant GH 2–4 IU daily
- Immediate (injected directly)
- 1–2 weeks
- 4–6 weeks
- Poor. Continuous elevation downregulates GH receptors within 8–12 weeks
- Fastest visible results but requires cycling or dose escalation to maintain effect; not sustainable long-term
- CJC-1295/Ipamorelin combo
- 60–90 min post-injection
- 3–5 weeks
- 10–14 weeks
- Good. Modified pulsatile pattern with extended half-life
- Comparable timeline to sermorelin with slightly longer inter-dose interval; CJC-1295/Ipamorelin offers flexibility for patients who cannot dose nightly
- MK-677 (ibutamoren) oral daily
- 90–120 min post-dose
- 2–3 weeks
- 8–10 weeks
- Moderate. Oral administration blunts peak GH response but maintains baseline elevation
- Non-injection alternative with comparable IGF-1 elevation; trade-off is increased appetite and potential insulin resistance with long-term use